All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
July 2024: Zeyzelf (rivastigmine) twice-weekly transdermal patches have been added
News
July 2024: Zeyzelf (rivastigmine) twice-weekly transdermal patches have been added
Zeyzelf (rivastigmine) twice-weekly transdermal patches 4.6mg/24hours and 9.5mg/24hours have been added as an amber (specialist input) option for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia.
They are reserved for patients where there is a clear clinical benefit i.e., administration of transdermal patches causes significant distress to the patient.
Click here for the formulary entry.
